The clinical efficacy of EGFR inhibitors (cetuximab, panitumumab, erlotinib, gefitinib and vandetanib) introduced in the clinical practice for the treatment of metastatic cancers is limited to a subgroup of patients with the majority of cancer patients showing either intrinsic or acquired resistance to these drugs [1]. This evidence concerns the gene EGFR and cancer.